Clinical Success Is No Longer One Number

By Andreas Dimakakos Director of Clinical Data, Kate Smietana Director, Knowledge and Thought Leadership, Panos Karelis VP of Commercial, Dimitris Skaltsas Co-founder & CEO | In biopharmaceutical R&D, where fewer than 1 in 10 development programs ultimately reach approval, risk assessment remains central to portfolio strategy and investment decisions.